Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

BACKGROUND: Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-α (IFN-...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson Coon, J S, Liu, Z, Hoyle, M, Rogers, G, Green, C, Moxham, T, Welch, K, Stein, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720220/
https://www.ncbi.nlm.nih.gov/pubmed/19568242
http://dx.doi.org/10.1038/sj.bjc.6605167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720220/
https://www.ncbi.nlm.nih.gov/pubmed/19568242
http://dx.doi.org/10.1038/sj.bjc.6605167

Ejemplares similares